Surveyed rheumatologists are open to prescribing emerging agents for psoriatic arthritis (PsA)
patients upon approval. That is good news for the PsA patients who fail to respond to TNF-á
inhibitors; treatment options are limited for these patients. Availability of the TNF-á inhibitors vastly
improved treatment of the disease and effected a sweeping change in the approach to managing PsA.
Several emerging agents offer novel approaches to treating PsA—will they prompt another shift in
management of this chronic and debilitating disease?
Get the Answers You Need to Shape Your Strategy
PsA a chronic, debilitating disease that is both • underdiagnosed and undertreated. What are the symptoms of PsA? How is the disease diagnosed? What are the risk factors for the disease? How many people in the United States and Europe have PsA? How will this population grow over the next ten years?
TNF-á inhibitors were the fi rst agents to receive approval for PsA. How are TNF-á inhibitors incorporated into rheumatologists’ treatment choices? How will emerging treatments compete with TNF-á inhibitors?
Because of the high cost and increased use of TNF-á inhibitors, the PsA market has experienced strong growth over the past few years. Will the PsA market continue to grow? How will emerging agents perform in the market?
Scope
Primary research: survey of U.S. rheumatologists.
Overview of PsA: etiology, symptoms, and diagnosis.
Current treatments: nonsteroidal anti-infl ammatory agents, conventional diseasemodifying antirheumatic drugs, and TNF-á inhibitors.
Epidemiology: prevalent cases of PsA in the United States, France, Germany, Italy, Spain, and the United Kingdom.
(0 items)
